Lateral Pharma

Executive Summary

Lateral Pharma is an Australian biotechnology company pioneering a novel therapeutic platform targeting LanC-like (LanCL) proteins, which play a key role in cellular stress protection. Its Stressed Cell Protective (SCP) platform aims to enhance cellular resilience, offering potential treatments for neuropathic pain, neurodegenerative diseases such as Alzheimer's, and infectious respiratory conditions. Founded in 2020 and currently in Phase 2 development, the company is advancing its lead candidate for neuropathic pain, with additional preclinical programs in Alzheimer's disease and infectious disease. The platform's first-in-class mechanism represents a promising approach to addressing significant unmet medical needs, particularly in chronic pain and neurodegeneration, where current treatments are limited. Lateral Pharma's innovative strategy positions it as a potential leader in the growing field of cellular protective therapies, though clinical validation remains a key milestone to derisk the platform.

Upcoming Catalysts (preview)

• H2 2026Phase 2 data readout for lead neuropathic pain candidate65% success
• H1 2026Initiation of Phase 1/2 trial for Alzheimer's disease candidate50% success
• H2 2026Potential partnership or licensing deal for infectious respiratory disease program40% success